Tirzepatide

Tirzepatide is a TGA-registered, prescription-only dual GIP and GLP-1 receptor agonist approved for type 2 diabetes, chronic weight management and obstructive sleep apnoea in adults with obesity. It produced the largest average weight loss yet seen from a medicine — around 20% in trials, and more than semaglutide head-to-head. The honest caveats: the GIP mechanism is still not fully understood, the withdrawal trial showed most of the benefit reverses when it stops, its cardiovascular outcome evidence is less mature than semaglutide's, and it interferes with oral contraception.

What tirzepatide is

Tirzepatide is a single engineered peptide that activates two gut-hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. That makes it structurally and pharmacologically different from semaglutide, which acts on GLP-1 alone. It is often described as a "twincretin" — a molecule built to do the job of two incretin hormones at once.

In Australia it is registered under a single brand name as a Schedule 4, prescription-only medicine. Its indications have expanded: type 2 diabetes first, then chronic weight management in eligible adults, then moderate-to-severe obstructive sleep apnoea in adults with obesity. It is given by injection at intervals set by the prescriber, with the amount increased in stages to improve tolerability.

The peptide is based on the native GIP sequence, modified to resist enzymatic breakdown and carrying a fatty acid chain that binds it to albumin — the same design strategy that gives semaglutide its long duration. It is deliberately an imbalanced agonist, activating the GIP receptor more powerfully than the GLP-1 receptor relative to the natural hormones. Why that imbalance produces the results it does is genuinely not settled.

How it works — and the part nobody can fully explain

The GLP-1 half is well understood. Activating the GLP-1 receptor amplifies insulin release from beta cells when glucose is elevated, suppresses glucagon in the same glucose-dependent way, slows gastric emptying so meals feel larger for longer, and — most importantly for weight — acts on receptors in the hypothalamic arcuate nucleus and the brainstem (area postrema, nucleus tractus solitarius) to increase satiety and reduce hunger. Our semaglutide guide sets that pathway out in detail. The glucose-dependence of the insulin effect is why the medicine alone carries little hypoglycaemia risk — though that changes alongside insulin or sulfonylureas.

The GIP half is where it gets interesting. GIP is the other major incretin, released from K cells in the upper small intestine when nutrients arrive. It also stimulates glucose-dependent insulin release, so the pancreatic effects are broadly additive — and adding GIP action restores an insulin response known to be blunted in type 2 diabetes.

Outside the pancreas, GIP's role is contested. It acts on adipose tissue, where it appears to promote the storage and buffering of dietary fat — at face value the opposite of what a weight-loss drug should do. And it acts in the brain, where GIP receptors in the hypothalamus and area postrema are increasingly thought to be the source of both the weight benefit and the improved tolerability: central GIP activation reduces food intake in animal models and may dampen nausea signalling, letting a person tolerate more GLP-1 effect than they otherwise could.

The awkward observation is that in preclinical models, GIP receptor agonists and antagonists can both produce weight loss when combined with GLP-1 activity, and both approaches are in clinical development. A mechanism that works when you turn a receptor on and when you turn it off is not yet fully characterised. Tirzepatide's clinical results are solid; the explanation for them is provisional — worth saying plainly, because the "dual mechanism" line is often presented as though it settled the matter.

What the human evidence actually shows

The weight results are the largest yet produced by a medicine. In SURMOUNT-1, adults with obesity and without type 2 diabetes lost roughly 15–21% of body weight over 72 weeks depending on treatment level, against about 3% on placebo, with lifestyle support in both arms. SURMOUNT-2, in people who also had type 2 diabetes, showed smaller reductions of roughly 13–15% — the consistent pattern in this class that coexisting diabetes blunts the response.

Head-to-head, it outperformed semaglutide. In SURMOUNT-5, tirzepatide produced around 20% average reduction versus roughly 14% for semaglutide at 72 weeks. That is a real and clinically meaningful difference in average outcome. It does not by itself make tirzepatide the right choice for any given person — comparative average efficacy is one input among tolerability, cost, supply, comorbidities and outcome evidence. Semaglutide vs tirzepatide works through that comparison.

Beyond weight, SURMOUNT-OSA showed meaningful reductions in apnoea–hypopnoea events in adults with obesity and obstructive sleep apnoea, supporting that registration. Trials in heart failure with preserved ejection fraction and metabolic liver disease have added further evidence; GLP-1s beyond weight loss covers where the class is heading.

Now the parts that are less comfortable.

The withdrawal trial is the most instructive result in the programme. SURMOUNT-4 ran an open-label lead-in and then randomised participants either to continue or to switch to placebo. Those who continued kept losing. Those who stopped regained a large proportion of what they had lost over the following months. This is the cleanest available demonstration that the effect is contingent on continued treatment. It is not a drug you take until you reach a goal; on current evidence it is a drug you take for as long as the benefit is worth the cost and risk.

Cardiovascular outcome evidence is less mature than semaglutide's. Semaglutide has a dedicated trial showing reduced major adverse cardiovascular events in people with obesity and established cardiovascular disease. Tirzepatide's outcome data is more recent and framed largely around non-inferiority to an active comparator rather than demonstrated superiority against placebo in a comparable non-diabetic population. If cardiovascular risk reduction rather than weight is the primary goal, that difference is relevant — raise it with your doctor, and confirm the current position, because this area is moving quickly.

Gastrointestinal side effects are common and cause discontinuation. Nausea, diarrhoea, vomiting and constipation dominate, typically worst during the escalation phase and easing for many people afterwards. In the trials a small but non-trivial percentage stopped because of adverse events, and real-world persistence is considerably lower than trial persistence, where participants had structured support and free medicine.

Lean mass. As with any substantial weight loss, part of what is lost is lean tissue. Fat mass falls proportionally more, but absolute lean mass falls too. Whether that has functional consequences, and how far resistance training and adequate protein mitigate it, is an open research question. Supply has also repeatedly failed to keep up with demand in this class, and Australian patients have been affected — continuity is a legitimate thing to ask about before starting.

Regulatory status in Australia

Tirzepatide is TGA-registered: evaluated for quality, safety and efficacy, and carrying an approved Product Information document listing indications, contraindications, interactions and warnings. That document is the practical dividing line between a registered medicine and a compounded or imported one.

PBS subsidy. Arrangements in this class differ by indication and have changed repeatedly — diabetes has been treated differently from weight management, which has generally not been subsidised. Do not rely on any summary, including this one: confirm the current PBS position with your prescriber or against the current schedule.

Compounded tirzepatide is prohibited and unsafe. Pharmacy compounding of GIP/GLP-1 receptor agonists was prohibited in Australia from late 2024, following TGA concern about preparations sold during the shortage period. The reasoning is worth understanding:

• They are not TGA-evaluated for identity, purity, sterility or strength.
• Some products marketed internationally used salt forms never tested in humans.
• Concentration and measurement errors with unregulated preparations have caused documented overdoses and hospital admissions overseas.
• There is no approved Product Information, no manufacturer accountability, and no proper adverse-event reporting pathway.

The TGA has also warned about counterfeit product in this class entering supply chains. Anything bought online, imported, or supplied through a gym or social media seller carries no assurance of what it contains. If a preparation is being offered at a notably low price, that price is the question. Compounded vs TGA-registered medicines explains how to tell them apart, as does our compounded vs registered explainer.

Advertising prescription-only medicines to the public is restricted in Australia. A clinic can discuss tirzepatide inside a consultation; a provider publicly promoting it with promised results is telling you something about how it operates.

Who it is for — and who it is not for

Registered use covers adults with type 2 diabetes; adults with obesity, or overweight with a weight-related health condition, alongside diet and physical activity; and adults with obesity and moderate-to-severe obstructive sleep apnoea.

It is not appropriate, or needs specialist input, in: pregnancy, breastfeeding, or planned near-term conception; a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, on the basis of rodent thyroid C-cell findings; previous pancreatitis; significant gastrointestinal disease including gastroparesis; type 1 diabetes; and active or past eating disorders. Insulin or sulfonylureas need reviewing concurrently for hypoglycaemia risk.

Two interactions deserve specific attention. First, oral contraception: by slowing gastric emptying, tirzepatide can reduce the absorption and effectiveness of the contraceptive pill, particularly around the escalation period, and product guidance recommends a non-oral or additional barrier method during that time. It is a genuinely consequential interaction that is easy to miss. Second, anaesthesia and endoscopy: delayed gastric emptying has been linked to retained stomach contents and aspiration risk, so any anaesthetist or endoscopist must be told you take it.

If low testosterone is part of your picture, obesity and sleep apnoea both suppress the hormonal axis described in our TRT guide.

Risks, monitoring and cost

Expect baseline assessment, closer review during the escalation phase when side effects peak, then ongoing review of weight, glucose where relevant, blood pressure, tolerability and whether the treatment is still delivering enough to justify continuing. A credible prescriber sets a stopping rule as well as a starting one. Serious but less common concerns include pancreatitis, gallbladder disease (partly a consequence of rapid weight loss itself), dehydration and kidney injury after severe vomiting or diarrhoea, and hypoglycaemia alongside certain diabetes medicines; severe or persistent abdominal pain warrants prompt medical attention.

Without subsidy this is an ongoing private medicine expense plus consultations plus pathology — and the withdrawal data means "ongoing" should be read literally. Telehealth weight services frequently add a programme fee. Ask for the full annual cost in writing before you commit.

What to ask a doctor

• Which registered indication applies to me, and why tirzepatide rather than another option?
• Is what you are prescribing the TGA-registered product, or a compounded or imported preparation?
• What does the comparative evidence mean for my goals — weight, glucose, sleep apnoea or cardiovascular risk?
• Am I eligible for any subsidy? What is the full annual cost including pathology?
• I use oral contraception — what do I need to change, and for how long?
• What side effects should I expect, when do they peak, and how do we manage them?
• How will we protect muscle mass and nutrition during weight loss?
• What happens if I stop, and is this long-term?
• How will supply interruptions be handled, and who is the registered prescriber?

FAQ

How is it different from semaglutide, and if it works better why would anyone use semaglutide? It activates two incretin receptors rather than one, and head-to-head produced greater average weight loss. But semaglutide has the more mature cardiovascular outcome evidence, and tolerability, cost, supply and individual response all matter. "Larger average effect" is not "better for you" — that is a clinical judgement, not a ranking.

Are compounded versions safe? No. Pharmacy compounding of GIP/GLP-1 receptor agonists was prohibited in Australia in late 2024, and imported copies are not evaluated for identity, purity, sterility or strength.

Does it affect the contraceptive pill? Yes — this is one of the more important practical points. Slowed gastric emptying can reduce oral contraceptive absorption, particularly during the escalation period, and product guidance recommends a non-oral method or an additional barrier method during that window. Raise it explicitly with your prescriber.

Where should I start? With a proper clinical assessment of your metabolic health, not with a product decision. Once you know what you are treating, you can compare doctor-supervised weight management clinics, take the right questions into the consultation, and check that your prescriber is registered.